Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).
Saved in:
| Title: | Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938). |
|---|---|
| Authors: | Villaruz LC; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Jin J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Wang H; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Lee JJ; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Luke JJ; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Rhee JC; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Waqar SN; Washington University School of Medicine, St. Louis, Missouri, USA., Shapiro GI; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Cleary J; Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Davar D; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Burns TF; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Verma R; UC Davis Comprehensive Cancer Center, Sacramento, California, USA., Amin M; University of Chicago Comprehensive Cancer Center, Chicago, Illinois, USA., Appleman L; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Ciombor KK; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Davis EJ; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Riess JW; UC Davis Comprehensive Cancer Center, Sacramento, California, USA., Dees EC; Division of Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA., Kim EJ; UC Davis Comprehensive Cancer Center, Sacramento, California, USA., Cardin D; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Guo J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Christner SM; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Deppas J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Parise AM; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Schmitz JC; Program in Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA., Guerrouahen BS; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Suchko M; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Contreras A; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Li L; Frederick National Laboratory for Cancer Research, Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick, Maryland, USA., Ferry-Galow KV; Frederick National Laboratory for Cancer Research, Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick, Maryland, USA., Chang TC; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Jiwani S; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Bakkenist CJ; Department of Radiation Oncology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Chu E; Montefiore Einstein Cancer Canter, Bronx, New York, USA., Gore SD; Division of Cancer Treatment and Diagnosis, Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA., Beumer JH; The Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, USA. |
| Source: | Cancer [Cancer] 2025 Nov 01; Vol. 131 (21), pp. e70157. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41160399 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Villaruz+LC%22">Villaruz LC</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Jin+J%22">Jin J</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Wang+H%22">Wang H</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Lee+JJ%22">Lee JJ</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Luke+JJ%22">Luke JJ</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Rhee+JC%22">Rhee JC</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Waqar+SN%22">Waqar SN</searchLink>; Washington University School of Medicine, St. Louis, Missouri, USA.<br /><searchLink fieldCode="AU" term="%22Shapiro+GI%22">Shapiro GI</searchLink>; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Cleary+J%22">Cleary J</searchLink>; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Davar+D%22">Davar D</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Burns+TF%22">Burns TF</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Verma+R%22">Verma R</searchLink>; UC Davis Comprehensive Cancer Center, Sacramento, California, USA.<br /><searchLink fieldCode="AU" term="%22Amin+M%22">Amin M</searchLink>; University of Chicago Comprehensive Cancer Center, Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Appleman+L%22">Appleman L</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Ciombor+KK%22">Ciombor KK</searchLink>; Vanderbilt University Medical Center, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Davis+EJ%22">Davis EJ</searchLink>; Vanderbilt University Medical Center, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Riess+JW%22">Riess JW</searchLink>; UC Davis Comprehensive Cancer Center, Sacramento, California, USA.<br /><searchLink fieldCode="AU" term="%22Dees+EC%22">Dees EC</searchLink>; Division of Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Kim+EJ%22">Kim EJ</searchLink>; UC Davis Comprehensive Cancer Center, Sacramento, California, USA.<br /><searchLink fieldCode="AU" term="%22Cardin+D%22">Cardin D</searchLink>; Vanderbilt University Medical Center, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Guo+J%22">Guo J</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Christner+SM%22">Christner SM</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Deppas+J%22">Deppas J</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Parise+AM%22">Parise AM</searchLink>; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Schmitz+JC%22">Schmitz JC</searchLink>; Program in Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Guerrouahen+BS%22">Guerrouahen BS</searchLink>; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Suchko+M%22">Suchko M</searchLink>; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Contreras+A%22">Contreras A</searchLink>; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Li+L%22">Li L</searchLink>; Frederick National Laboratory for Cancer Research, Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Ferry-Galow+KV%22">Ferry-Galow KV</searchLink>; Frederick National Laboratory for Cancer Research, Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Chang+TC%22">Chang TC</searchLink>; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Jiwani+S%22">Jiwani S</searchLink>; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Bakkenist+CJ%22">Bakkenist CJ</searchLink>; Department of Radiation Oncology, UPMC Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Chu+E%22">Chu E</searchLink>; Montefiore Einstein Cancer Canter, Bronx, New York, USA.<br /><searchLink fieldCode="AU" term="%22Gore+SD%22">Gore SD</searchLink>; Division of Cancer Treatment and Diagnosis, Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Beumer+JH%22">Beumer JH</searchLink>; The Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220374236%22">Cancer</searchLink> [Cancer] 2025 Nov 01; Vol. 131 (21), pp. e70157. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Journal Article; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0374236 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0142 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220008543X%22">0008543X </searchLink><i>NLM ISO Abbreviation: </i>Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41160399 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/cncr.70157 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e70157 Titles: – TitleFull: Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Villaruz LC – PersonEntity: Name: NameFull: Jin J – PersonEntity: Name: NameFull: Wang H – PersonEntity: Name: NameFull: Lee JJ – PersonEntity: Name: NameFull: Luke JJ – PersonEntity: Name: NameFull: Rhee JC – PersonEntity: Name: NameFull: Waqar SN – PersonEntity: Name: NameFull: Shapiro GI – PersonEntity: Name: NameFull: Cleary J – PersonEntity: Name: NameFull: Davar D – PersonEntity: Name: NameFull: Burns TF – PersonEntity: Name: NameFull: Verma R – PersonEntity: Name: NameFull: Amin M – PersonEntity: Name: NameFull: Appleman L – PersonEntity: Name: NameFull: Ciombor KK – PersonEntity: Name: NameFull: Davis EJ – PersonEntity: Name: NameFull: Riess JW – PersonEntity: Name: NameFull: Dees EC – PersonEntity: Name: NameFull: Kim EJ – PersonEntity: Name: NameFull: Cardin D – PersonEntity: Name: NameFull: Guo J – PersonEntity: Name: NameFull: Christner SM – PersonEntity: Name: NameFull: Deppas J – PersonEntity: Name: NameFull: Parise AM – PersonEntity: Name: NameFull: Schmitz JC – PersonEntity: Name: NameFull: Guerrouahen BS – PersonEntity: Name: NameFull: Suchko M – PersonEntity: Name: NameFull: Contreras A – PersonEntity: Name: NameFull: Li L – PersonEntity: Name: NameFull: Ferry-Galow KV – PersonEntity: Name: NameFull: Chang TC – PersonEntity: Name: NameFull: Jiwani S – PersonEntity: Name: NameFull: Bakkenist CJ – PersonEntity: Name: NameFull: Chu E – PersonEntity: Name: NameFull: Gore SD – PersonEntity: Name: NameFull: Beumer JH IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 11 Text: 2025 Nov 01 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1097-0142 Numbering: – Type: volume Value: 131 – Type: issue Value: 21 Titles: – TitleFull: Cancer Type: main |
| ResultId | 1 |
